⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LLY News
Eli Lilly & Co.
Brightmeds Tirzepatide Investigated: Is It Safe and Legit for Weight Loss? Exploring Safety, Side Effects, and Results (2026 Analysis)
globenewswire.com
LLY
KOMO Biosciences Appoints Patient Advocate Tom Whitehead and Immunotherapy Pioneer Michael Kalos, Ph.D. to Advisory Board
businesswire.com
JNJ
LLY
NVS
Biocom Announces Powerhouse Keynote Panel Featuring Heads of Discovery and Research & Development from AbbVie, Amgen and Eli Lilly at 2026 Global Partnering & Investor Conference
businesswire.com
ABBV
AMGN
LLY
The Inner Circle Acknowledges Dr. David Thrasher as a Pinnacle Professional for Leadership in Healthcare and Public Service
prnewswire.com
LLY
HD
Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
NVO
IONS
PFE
REGN
LXRX
VRTX
LLY
Single-Use Bioprocessing Market Projected to Reach US$ 122.92 Billion by 2035, Supported by Expansion of Biomanufacturing Capacity Says Astute Analytica
globenewswire.com
TMO
AMGN
PFE
BMY
GILD
REGN
AZN
LLY
MRK
GSK
Global Oncology Clinical Trials Market Projected to Reach US$ 25.61 Billion by 2035, Supported by Advances in Precision and Targeted Therapies Says Astute Analytica
globenewswire.com
MAR
LLY
Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction
businesswire.com
LLY
SNY
Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer
prnewswire.com
LLY
Shed GLP-1 Weight Loss Review 2026: Examining the Telehealth Platform's Process, Pricing, and Medication Options
accessnewswire.com
NVS
LLY